公开(公告)号：EP3194447A1

公开(公告)日：2017-07-26

申请号：EP15763621.8

申请日：2015-09-17

申请人： Novo Nordisk A/S

发明人： PETERSEN, Helle Heibroch ,  KROGH, Berit Olsen ,  BREINHOLT, Jens ,  KOFOD-HANSEN, Mikael ,  HILDEN, Ida

IPC分类号： C07K16/38 ,  C07K16/46 ,  A61K39/395

CPC分类号： C07K16/38 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.

摘要翻译： 该申请公开了能够特异性且同时结合TFPI内的两个表位（1-161）的双特异性TFPI抗体。 即使在TFPI浓度升高的情况下，这种双特异性抗体通过中和TFPI强烈增强凝血酶的产生。 本发明的双特异性抗体或包含它们的组合物可用于治疗患有凝血病的受试者。

公开(公告)号：EP2970499A1

公开(公告)日：2016-01-20

申请号：EP14710541.5

申请日：2014-03-14

申请人： Novo Nordisk A/S

发明人： OLSEN KROGH, Berit ,  KOFOD-HANSEN, Mikael ,  HILDEN, Ida ,  HEIBROCH PETERSEN, Helle ,  PETERSEN, Lars Christian

IPC分类号： C07K16/38 ,  C07K16/46

CPC分类号： C07K16/38 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

摘要： The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPIα, even where the concentration of TFPI is abnormally elevated.

摘要翻译： 应用程序盘松两个特定单TFPI抗体的组合，worin一种抗体是能够特异性结合TFPI（1-181），而另一个抗体是能够特异性结合TFPI（182-276），以及双特异性抗TFPI抗体的 从两个搜索单特异性抗体。 两个两个单特异性抗体的组合和所述双特异性抗体通过中性伊辛全长TFPIα强烈增强凝血酶产生，即使在TFPI的浓度异常升高。

公开(公告)号：EP2542257A4

公开(公告)日：2013-11-13

申请号：EP11751244

申请日：2011-03-01

申请人： BAYER HEALTHCARE LLC

发明人： SCHOLZ PETER ,  WANG ZHUOZHI ,  PAN JUNLIANG ,  GRUDZINSKA JOANNA ,  VOTSMEIER CHRISTIAN ,  TEBBE JAN ,  BIRKENFELD JOERG ,  WOBST NINA ,  BRUECKNER SIMONE ,  STEINIG SUSANNE

IPC分类号： C07K16/38 ,  A61K39/00 ,  A61K39/395

CPC分类号： C07K16/38 ,  A61K2039/505 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/21

摘要： Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

公开(公告)号：EP2514821A4

公开(公告)日：2013-08-28

申请号：EP10837676

申请日：2010-12-16

申请人： SCHOOL JURIDICAL PERSON KITASATO INST ,  NIPRO CORP

发明人： HOSHI FUMIO

IPC分类号： C12N15/09 ,  C07K14/81 ,  C07K16/38 ,  G01N33/53

CPC分类号： C07K16/38 ,  C07K14/70539 ,  C07K14/8139 ,  C07K16/2833 ,  G01N33/6893 ,  G01N2800/347

公开(公告)号：EP2459213A1

公开(公告)日：2012-06-06

申请号：EP10742942.5

申请日：2010-07-29

申请人： Amgen Inc.

发明人： BLACK, Roy, A. ,  LI, Peng ,  SILVERMAN, Joshua ,  KING, Chadwick, T.

IPC分类号： A61K38/57 ,  C07K14/81 ,  C07K16/38

CPC分类号： C07K14/81 ,  A61K38/00 ,  A61K38/57 ,  C07K7/08 ,  C07K14/8146 ,  C07K16/38 ,  C07K2317/21 ,  C07K2317/76

摘要： The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.

公开(公告)号：EP2391654A1

公开(公告)日：2011-12-07

申请号：EP10735454.0

申请日：2010-01-27

申请人： Industrial Technology Research Institute

发明人： LIN, Wei-Ya ,  YEH , Mary Ya-Ping ,  TSENG, Tzu-Ling ,  CHENG, Ping-Fu ,  HSU, Tsai-Wei ,  LI, Hung-Yi ,  CHEN, Yi-Ting ,  LIN, Yuh-Feng ,  CHEN, Giien-Shuen ,  LI , Yen-Peng

IPC分类号： C07K16/38 ,  C07K16/18 ,  C40B30/00 ,  G01N33/53 ,  G01N33/573 ,  G01N33/68 ,  C07K14/81 ,  C07K14/47

CPC分类号： G01N33/6893 ,  G01N2333/4728 ,  G01N2333/52 ,  G01N2333/71 ,  G01N2333/8125 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/56

摘要： Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha- 1 antitrypsin, urine alpha- 1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.

公开(公告)号：EP2087002A4

公开(公告)日：2010-06-30

申请号：EP07871262

申请日：2007-10-26

申请人： LPATH INC

发明人： SABBADINI ROGER A ,  GARLAND WILLIAM A ,  HANSEN GENEVIEVE ,  JONES STEVEN TARRAN ,  WILLIAMS DAVID GARETH

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K16/18 ,  C07K16/38 ,  C12N5/10 ,  C12N5/12 ,  C12N15/00 ,  C12P21/08 ,  G01N33/53

CPC分类号： C07K16/44 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

公开(公告)号：EP1864678A1

公开(公告)日：2007-12-12

申请号：EP07007638.5

申请日：1995-06-06

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： Chader, Gerald J. ,  Becerra, Sofia Patricia ,  Schwartz, Joan P. ,  Taniwaki, Takayuki

IPC分类号： A61K38/57 ,  C07K16/38 ,  G01N33/53 ,  C07K14/81

CPC分类号： C07K14/811 ,  A61K38/00 ,  C07K14/475 ,  C07K16/38

摘要： Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF -BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and use of these variants on: 1) neuronal differentiation (neurotrophic effect), 2) neuron survival (neuronotrophic effect), and 3) glial inhibition (gliastatic effect) are described.

摘要翻译： 编码称为色素上皮衍生因子（PEDF）的神经营养蛋白的核酸，被称为rPEDF的PEDF的截短形式，以及等效蛋白质，包含这种核酸的载体，其中引入了这样的载体的宿主细胞，重组方法 产生PEDF，rPEDF和相应的蛋白质，rPEDF蛋白和rPEDF和PEDF-BP，-BX和BA的相应蛋白质和通过重组方法产生的PEDF蛋白。 这些变体的作用和用途如下：1）神经元分化（神经营养作用），2）神经元存活（神经营养作用）和3）胶质细胞抑制（神经影响作用）。

公开(公告)号：EP1509166B1

公开(公告)日：2007-12-05

申请号：EP03757374.8

申请日：2003-06-06

申请人： ANITOX CORPORATION

发明人： PIMENTEL, Julio

IPC分类号： A61K39/395 ,  A23K1/00 ,  C07K16/38 ,  C07K16/40 ,  C07K16/16

CPC分类号： C07K16/40 ,  A23K20/10 ,  A23K20/147 ,  A23K50/40 ,  A23K50/50 ,  A23K50/75 ,  A61K2039/505 ,  C07K2317/23

摘要： A method for improving body weight gain and increasing feed conversion efficiency of in animals by feeding the animals a diet containing antibodies against anti-nutritional factors in food.

公开(公告)号：EP1598368A4

公开(公告)日：2007-07-25

申请号：EP04703509

申请日：2004-01-20

申请人： CHUGAI PHARMACEUTICAL CO LTD

发明人： KOGA TAKAKI ,  KIMURA NAOKI ,  YOSHINO TAKESHI ,  ONO KOICHIRO

IPC分类号： A61P7/02 ,  C07K14/81 ,  C07K16/38 ,  C12N15/13 ,  C12P21/08 ,  A61K39/395 ,  A61P7/00 ,  A61P31/00

CPC分类号： C07K16/38 ,  C07K14/8121 ,  C07K2317/50 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： It is intended to provide an anti-PCI antibody having a function of neutralizing protein C inhibitor (PCI) and utilization thereof. By producing and screening an anti-PCI antibody, an anti-PCI antibody inhibiting the functions of PCI of inhibiting the formation and activity of activated protein C (aPC) is successfully isolated. This antibody regulates the functions of PCI of inhibiting the formation of aPC and/or inactivating aPC, which makes it usable in maintaining the activity of aPC and sustaining the effects of the physiological activities of aPC of preventing the blood coagulation system from activation or an antiinflammatory function. It is also intended to provide utilization of the above antibody in treating thrombosis, sepsis, and so on using aPC. In a treatment with the administration of aPC, the administration of the above antibody contributes to the sustainment of the therapeutic effects. This antibody is usable in treating and preventing thrombosis, sepsis and so on.